Abbott Laboratories (Pakistan) Limited

ABOT

PK0025701019

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 18:00:00 2024-05-23 EDT			5-day change	1st Jan Change
680.3 ^PKR	-1.37%		+1.76%	+47.82%

05-03	Abbott Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-30	Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Abbot Laboatories Ltd. to Cease Asif Jooma as Chief Executive Officer, Effective February 24, 2013

December 24, 2012 at 06:09 am

Abbot Laboatories (Pakistan) Ltd. announced that Mr. Asif Jooma will cease to be the Chief Executive Officer of the company with effect from the close of business on February 24, 2013, after having successfully led the company for almost six years, to pursue interest outside of Abbott.

Latest news about Abbott Laboratories (Pakistan) Limited

Abbott Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Abbott Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-27	CI
Abbott Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-01	CI
Abbott Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-30	CI
Abbott Laboratories Announces Board Changes	22-08-25	CI
Abbott Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-27	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-27	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-23	CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-26	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-28	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-28	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-29	CI
Abbott Laboratories Proposes Cash Dividend for the Financial Year Ended December 31, 2019	20-03-18	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-02	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-17	CI
Abbott Laboratories Limited Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-16	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2019	19-04-23	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2018	19-02-21	CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended Sept. 30, 2018	18-10-19	CI

Chart Abbott Laboratories (Pakistan) Limited

Duration

Period

Chart Abbott Laboratories (Pakistan) Limited

More charts

Company Profile

Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, womenâs health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Companyâs easy-to-use test strips require only tiny blood samples while its meters provide results and reports.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBOTT LABORATORIES (PAKISTAN) LIMITED	+47.82%	243M
ELI LILLY AND COMPANY	+38.94%	728B
NOVO NORDISK A/S	+33.05%	603B
JOHNSON & JOHNSON	-5.53%	360B
MERCK & CO., INC.	+18.82%	332B
ABBVIE INC.	+1.54%	279B
ASTRAZENECA PLC	+16.00%	244B
NOVARTIS AG	+8.09%	207B
ROCHE HOLDING AG	-5.77%	205B
AMGEN INC.	+6.44%	164B